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Resveratrol is a polyphenolic stilbene with  anti-oxidant, anti-inflammatory and anti-tumoral bioactivities . High
concentrations of resveratrol (50 μM) have been reported to induce HbF synthesis in an in vitro model of normal and
beta-thalassemic erythropoiesis (Fibach E. Int J Mol Med 2012; Rodrigue CM. BJH 2001) and to improve erythropoiesis
in a mouse model for Fanconi Anemia (Zhang Q. Blood 2010). Beta thalassemia (b-thal) is characterized by ineffective
erythropoiesis and increased cellular oxidative stress. We studied the effects of resveratrol (5 µM) on erythropoiesis in
vitro from peripheral CD34+ cells of healthy and b-thal subjects. Erythroid maturation was evaluated at 7, 9, 11 and 14
days of culture by cytofluorimetric analysis using the CD71-GPA-CD36 strategy that allows to separate CFU-E, Pro-E,
Int-E and Late-Erythroblasts (Merryweather-Clarke AT. Blood 2011). Resveratrol reduced cell growth in both cell types,
with a reduction of CFU-E, increased Int-E at day 7 and 9,  and increased Int-E and Late-E at 11 and 14 days. The early
maturation of erythroid progenitors was confirmed by morphological analysis of the cells. We sorted CFU-E cells (at 7
days) from resveratrol treated and untreated cells and analyzed the cell cycle, cyclinD1 and p21 expression. In both
cell types resveratrol induced increased frequency of S-G2/M cells compared to untreated cells with increased p21
levels, suggesting decreased cycling of CFU-E with increased maturation of erythroblasts. No changes of gamma chain
mRNA levels were present in cells treated with resveratrol (5 µM). Since FOXO3 is a key regulator of erythroid redox
required for normal erythroid maturation (Marinkovic D. JCI 2007), FOXO3 expression and activity was assessed in
sorted CFU (7day) and Int-E (11 day) with and without resveratrol. FOXO3a mRNA levels were increased in resveratrol
treated cells in both sorted cell populations. We used nuclear localization as a surrogate assay for FOXO3a activity and
found resveratrol  increased the overall expression of FOXO3 protein in the nucleus without impacting significantly the
nuclear/cytoplasmic ratio. Interestingly, resveratrol did not appear to modify FOXO1 expression or subcellular
localization. These results suggest that resveratrol enhances specifically expression of FOXO3 in human erythroblasts.
Dietary resveratrol supplementation (2.4 mg/Kg) was studied in wild-type and Hbb3th+/- mice (2 months of age) for 6
months. In resveratrol Hbb3th+/- treated mice increased Hb levels (8.3±0.6 vs 10.3±0.5 g/dL, n=12; P<0.05) and
decreased reticulocyte count (33.9±0.8 vs 23.7± 8.2 %, n=12; P<0.05) were observed. Significant increased MCV
(34.6±0.6 vs 41.6± 5.4 fL, n=12; P<0.05) and MCH ( 9.7± 0.6 vs 12.8 ± 2.1 pg, n=12; P<0.05) were also noted. Flow
cytometric evidence of decreased ineffective erythropoiesis and reduced spleen/ body weight ratio were also observed.
These data indicate that resveratrol affects erythroid maturation both in vitro and in vivo, and that these effects have
possible therapeutic relevance for the treatment of thalassemias. 
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